SIGNAL // LOADING
Loading page
Glossary term
Ozempic
Also known as Semaglutide (T2D indication)
Brand-name semaglutide approved for type 2 diabetes. Often used off-label for weight loss.
Ozempic is Novo Nordisk's once-weekly semaglutide formulation approved for type 2 diabetes. SUSTAIN trials showed 1.5-1.8% HbA1c reduction at max dose plus secondary weight loss. It is not FDA-approved for weight loss - that indication sits with Wegovy (same molecule, different labeling). Insurance coverage and availability vary, which is why ALUKARD evaluates Wegovy, Ozempic, and compounded semaglutide side-by-side during eligibility review.
Medically reviewed byDr. Lena Okafor, MD
Medical Director - updated April 2026How we review
External references
Related
Connected context
Related terms
Related guides
GLP-1 eligibility explained: who qualifies, who doesn't, and whyTirzepatide vs semaglutide: how to think about the choiceWhat a comprehensive metabolic panel actually tells youProvider-reviewed care vs DIY supplementation: when each makes sensePCOS labs: the markers that actually drive the planGLP-1 side effects: what's normal, what needs review, what stops the protocolHolding the loss after GLP-1: protein, training, and the maintenance planFasting insulin and HOMA-IR: the metabolic signal that precedes A1c by yearsCreatine, protein, and the two supplements that actually moved your labsWeight-loss plateaus on GLP-1: what to change first